Neurologic and psychiatric complications of antiretroviral agents

Journal of the Association of Nurses in AIDS Care

Volumn 16, Issue 5, 2005, Pages 35-48

  Raines, Charles ^a   Radcliffe, Olivia ^b   Treisman, Glenn J ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Antiretroviral; HAART; HIV; Neurologic and psychologic complications

Indexed keywords

EID: 26944487612     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jana.2005.07.004     Document Type: Article

References (79)

1. Arendt, G., & von Giesen, H. J. (2002). Antiretroviral therapy regimens for neuro-AIDS. Current Drug Targets - Infectious Disorders, 2, 187-192.
2. Asch, S. M., Kilbourne, A. M., Gifford, A., L, Burnam, M. A., Turner, B., Shapiro, M. F., et al. (2003). Underdiagnosis of depression in HIV. Who are we missing? Journal of General Internal Medicine, 18, 450-460.
3. Aweeka, F., Jayewardene, A., Staprans, S., Bellibas, S. E., Kearney, B., Lizak, P., et al. (1999). Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology, 20, 39-43.
4. Badaro R., DeJesus E., Lazzarin A., Jemsek J., Clotet B., Wilber R., et al. (2003, July). Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and one NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045 (Abstract No. 118, 2003). Paper presented at the Second International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris,.
5. Barreiro, P., García-Benayas, T., Soriano, V., & Gallant, J. (2002). Simplification of antiretroviral treatment - How to sustain success, reduce toxicity and ensure adherence avoiding PI use. AIDS Reviews, 4, 233-241.
6. Barreiro, P., Soriano, P., Bianco, F., Casimiro, C., de la Cruz, J. J, & Gonzalez-Lahoz, J. (2000). Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS, 14, 807-812.
7. Bartlett, J. A., DeMasi, R., Quinn, J., Moxham, C., & Rousseau, F. (2001). Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS, 15, 1369-1377.
8. Bartlett, J. G., & Gallant, J. E. (2004). 2004 Medical Management of HIV Infection. Baltimore: Johns Hopkins University Centennial.
9. Bing, E. G, Burnam, M. A., Longshore, D., Fleishman, J. A., Sherbourne, C. D., London, A. S., et al. (2001). Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Archives of General Psychiatry, 58, 721-728.
10. Bogart, L. M., Kelly, J. A., Catz, S. L., & Sosman, J. M. (2000). Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. Journal of the Acquired Immune Deficiency Syndromes, 23, 396-404.
11. Bonfanti, P., Valsecchi, L., Parazzini, F., Carradori, S., Pusterla, L., Fortuna, P., et al. (2000). Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study. Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. Journal of the Acquired Immune Deficiency Syndromes, 23, 236-245.
12. Childs, E. A., Lyles, R. H., Seines, O. A., Chen, B., Miller, E. N., Cohen, B. A., et al. (1999). Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology, 52, 607-613.
13. Ciesla, J. A., & Roberts, J. E. (2001). Meta-analysis of the relationship between HIV infection and risk for depressive disorders. American Journal of Psychiatry, 158, 725-730.
14. Clark, M. R. (2000). Pharmacological treatments for chronic non-malignant pain.International Review of Psychiatry, 12, 148-156.
15. Clifford, D. B., Evans S., Yang, Y., Acosta, E., Goodkin, K., & Gulick, R. M. (2004). Impact of efavirenz (EFV) on neuropsychological performance, mood and sleep behavior in HIV-positive individuals. Antiviral Therapy, 8(Suppl 1), S196-S197. Abstract No. 54.
16. Conway, B. (2000). Initial therapy with protease inhibitor-sparing regimens: Evaluation of nevirapine and delavirdine. Clinical Infectious Diseases, 30 (Suppl 2), S130-134.
17. Cruess, D. G., Douglas, S. D., Petitto, J. M., Leserman, J., Ten Have, T, Gettes, D., et al. (2003). Association of depression, CD8+ T lymphocytes, and natural killer cell activity: implications for morbidity and mortality in human immunodeficiency virus disease. Current Psychiatry Reports, 5, 445-450.
18. Cruess, D. G., Petitto, J. M, Leserman, J., Douglas, S. D., Gettes, D. R., Ten Have, T. R, et al. (2003). Depression and HIV infection: impact on immune function and disease progression. CNS Spectrums, 8, 52-58.
19. D'Arminio Monforte, A, Cinque, P., Mocroft, A., Goebel, F. D., Antunes, F., Katlama, C., et al. (2004). Changing incidence of central nervous system diseases in the EuroSIDA cohort. Annals of Neurology, 55, 320-328.
20. Department of Heath and Human Services. (2005). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. April 7, 2005. Retrieved April 21, 2005, from http://AIDSinfo.nih.gov
21. Dragovic, G., & Jevtovic, D. (2003). Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients. Antiviral Chemistry and Chemotherapy, 14, 281-284.
22. Farinpour, R., Miller, E. N., Satz, P., Seines, O. A., Cohen, B. A., Decker, J. T., et al. (2003). Psychosocial risk factors of HIV morbidity and mortality: findings from the Multicenter AIDS Cohort Study (MACS). Journal of Clinical and Experimental Neuropsychology, 25, 654-670.
23. Fernandez, F. (2002). Neuropsychiatric aspects of human immunodeficiency virus (HIV) infection. Current Psychiatry Reports, 4, 228-231.
24. Filippi, C. G., Sze, G., Farber, S. J., Shahmanesh, M., & Selwyn, P. A. (1998). Regression of HIV encephalopathy and basal ganglia signal intensity abnormality at MR imaging in patients with AIDS after the initiation of protease inhibitor therapy. Radiology, 206, 491-498.
25. Fumaz, C. R., Tuldrà, A., Ferrer, M. J., Paredes, R., Bonjoch, A., Jou, T., et al. (2002). Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. Journal of the Acquired Immune Deficiency Syndromes, 29, 244-253.
26. Gallego, L., Barreiro, P., del Rio, R, Gonzalez de Requena, D, Rodriguez-Albarino, A., et al. (2004). Analyzing sleep abnormalities in HIV-infected patients treated with efavirenz. Clinical Infectious Disease, 38, 430-432.
27. Gathe, J.C., Jr., Ive P., Wood, R., Schurmann, D., Bellos, N.C., DeJesus, E., et al. (2004). SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18, 1529-1537.
28. Gatti, G., Di Biagio, A, Casazza, R., De Pascalis, C, Bassetti, M., Cruciani, M., et al. (1999). The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS, 13, 2083-2089.
29. Gisslen, M., Norkrans, G., Svennerholm, B., & Hagberg, L. (1997). The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. Journal of Infectious Diseases, 175, 434-437.
30. Glynn, S. L., & Yazdanian, M. (1998). In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. Journal of Pharmaceutical Sciences, 87, 306-310.
31. Guest J. L., DeSilva K. E., Flaherty T. D., Le Flore D. B., & Rimland D. (2002). Incidence of CNS effects in patients with a history of mental health disorders and/or substance abuse starting an efavirenz-containing regimen: Data from HAVACS. XIV International AIDS Conference Abstracts. Abstract No. TuPeB4502.
32. Hinkin, C. H., Castellon, S. A., Durvasula, R. S., Hardy, D. J., Lam, M. N., Mason, K. I., et al. (2002). Medication adherence among HIV+ adults. Effects of cognitive dysfunction and regimen complexity. Neurology, 59, 1944-1950.
33. Kemmler, G., Schmied, B., Shetty-Lee, A., Zangerle, R., Hinterhuber, H., Schussler, G., et al. (2003). Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathology, 13, 195-210.
34. Kendler, K. S., Gallagher, T. J., Abelson, J. M., & Kessler, R. C. (1996). Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey. Archives of General Psychiatry, 53, 1022-1031.
35. Kieburtz, K., Zettelmaier, A. E., Ketonen, L., Tuite, M., & Caine, E. D. (1991). Manic syndrome in AIDS. American Journal of Psychiatry, 148, 1068-1070.
36. Kline, M. W., Dunkle, L. M., Church, J. A., Goldsmith, J. C., Harris, A. T., Federici, M. E., et al. (1995). A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection. Pediatrics, 96, 247-252.
37. th Conference on Retrovirals and Opportunistic Infections, Seattle, WA.
38. Lambotte, O., Deiva, K., & Tardieu, M. (2003). HIV-1 persistence, viral reservoir, and the central nervous system in the HAART era. Brain Pathology, 13, 95-103.
39. Lopez, O. L., Becker, J. T., Dew, M. A., & Caldararo, R. (2004). Risk modifiers for peripheral sensory neuropathy in HIV infection/AIDS. European Journal of Neurology, 11, 97-102.
40. Lucas, G. M., Chaisson, R. E., & Moore, R. D. (2003). Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study. Journal of the Acquired Immune Deficiency Syndromes, 33, 321-328.
41. Martin, C., Solders, G., Sonnerborg, A., & Hansson, P. (2000). Antiretroviral therapy may improve sensory function in HIV-infected patients: a pilot study. Neurology, 54, 2120-2127.
42. Marzolini, C., Telenti, A., Decosterd, L. A., Greub, G., Biollaz, J., & Buclin, T. (2001). Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS, 15, 71-75.
43. Maxwell, S., Scheftner, W. A., Kessler, H. A., & Busch, K. (1988). Manic syndrome associated with zidovudine treatment. Journal of the American Medical Association, 259, 3406-3407.
44. McArthur, J. C., McClernon, D. R., Cronin, M. F., Nance-Sproson, T. E., Saah, A. J., St Clair, M, et al. (1997). Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Annals of Neurology, 42, 689-698.
45. Medical Economics Co., Inc. (2005). Efavirenz (Sustiva). Physicians' Desk Reference (pp. 1069-1075). Montvale, NJ: Author.
46. Nath, A., & Berger, J. (2004). HIV dementia. Current Treatment Options in Neurology, 6, 139-151.
47. Neuenburg, J. K., Brodt, H.R., Herndier, B. G., Bickel, M., Bacchetti, P., Price, R. W., et al. (2002). HIV-related neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy. Journal of the Acquired Immune Deficiency Syndromes, 31, 171-177.
48. Nunez, M., Gonzalez de Requena, D, Gallego, L., Jimenez-Nacher, I., Gonzalez-Lahoz, J., & Soriano, V. (2001). Higher efavirenz plasma levels correlate with development of insomnia. Journal of the Acquired Immune Deficiency Syndromes, 28, 399-400.
49. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853-860.
50. Pérez-Molina, J. A. (2002). Safety and tolerance of efavirenz in different antiretroviral regimens: Results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clinical Trials, 3, 279-286.
51. Pizzo, P. A., Eddy, J., Falloon, J., Balis, F. M., Murphy, R. F., Moss, H., et al. (1988). Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. New England Journal of Medicine, 319, 889-896.
52. Pukay-Martin, N. D, Cristiani, S. A., Saveanu, R., & Bornstein, R. A. (2003). The relationship between stressful life events and cognitive function in HIV-infected men. Journal of Neuropsychiatry and Clinical Neurosciences, 15, 436-441.
53. Puzantian, T. (2002). Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy, 22, 930-933.
54. Rachilis, A., & Fanning, M. M. (1993). Zidovudine toxicity. Clinical features and management. Drug Safety, 8, 312-320.
55. Repetto, M. J., Evans, D. L., Cruess, D. G., Gettes, D. R., Douglas, S. D., & Petitto, J. M. (2003). Neuropsychopharmacologic treatment of depression and other neuropsychiatric disorders in HIV-infected individuals. CNS Spectrums, 8, 59-63.
56. Resnick, L., Berger, J. R., Shapshak, P., & Tourtellotte, W. W. (1988). Early penetration of the blood-brain barrier by HIV. Neurology, 38, 9-14.
57. Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volderbing, P. A., Laskin, O. L., et al. (1987). The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind placebo-controlled trial. New England Journal of Medicine, 317, 192-197.
58. Sacktor, N. C., Bacellar, H., Hoover, D. R., Nance-Sproson, T. E., Seines, O. A., Miller, E. N., et al. (1996). Psychomotor slowing in HIV infection: A predictor of dementia, AIDS and death. Journal of Neurovirology, 2, 404-410.
59. Sewell, D. D., Jeste, D. V., Atkinson, J. H., Heaton, R. K., Hesselink, J. R., Wiley, C., et al. (1994). HIV-associated psychosis: a study of 20 cases. San Diego HIV Neurobehavioral Research Center Group. American Journal of Psychiatry, 151, 237-242.
60. Simpson, D. M. (1999). Human immunodeficiency virus-associated dementia: review of pathogenesis, prophylaxis, and treatment studies of zidovudine therapy. Clinical Infectious Diseases, 29, 19-34.
61. Singh, N., Squier, C., Sivek, C., Wagener, M., Nguyen, M. H., & Yu, V. L. (1996). Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance. AIDS Care, 8, 261-269.
62. Solas, C., Lafeuillade, A., Halfon, P., Chadapaud, S., Hittinger, G., & Lacarelle, B. (2003). Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrobial Agents and Chemotherapy, 47, 238-243.
63. Starace, F., Dijkgraaf, M., Houweling, H., Postma, M., & Tramarin, A. (1998). HIV-associated dementia: Clinical, epidemiological and resource utilization issues. AIDS Care, 10 (Suppl 2), S113-S121.
64. Starace, F., Ammassari, A., Trotta, M.P., Murri, R., De Longis, P., Izzo, C., et al. (2002). Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. Journal of the Acquired Immune Deficiency Syndromes, 31(Suppl 3), S136-139.
65. Starace, F., Bartoli, L., Aloisi, M.S., Antinori, A., Narciso, P., Ippolito, G., et al. (2002). Cognitive and affective disorders associated to HIV infection in the HAART era: Findings from the NeuroICONA study. Cognitive impairment and depression in HIV/AIDS. The NeuroICONA study. Acta Psychiatrica Scandinavia, 106, 20-26.
66. Tate, D., Paul, R. H., Flanigan, T. P., Tashima, K., Nash, J., Adair, C., et al. (2002). The impact of apathy and depression on quality of life in patients infected with HIV. AIDS Patient Care and STDs, 17, 115-120.
67. Tostes, M. A, Chalub, M., & Botega, N. J. (2004). The quality of life of HIV-infected women is associated with psychiatric morbidity. AIDS Care, 16, 177-186.
68. Treisman, G. J., & Kaplin, A. I. (2002). Neurologic and psychiatric complications of antiretroviral agents. AIDS, 16, 1201-1215.
69. Valente, S. M. (2003). Depression and HIV disease. Journal of the Association of Nurses in AIDS Care, 14, 41-51.
70. van den Brande G., Marquie Beck J., Capparelli E., Ellis R., McCutchan A. Hermes A., et al. (2005, February). Kaletra independently reduces HIV replication in cerebrospinal fluid (Abstract No. 403). Paper presented at the 12th Conference on Retrovirals and Opportunistic Infections, Boston..
71. van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., et al. (2004). Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet, 363, 1253-1263.
72. Verma, S, Micsa, E., Estanislao, L., & Simpson, D. (2004). Neuromuscular complications in HIV. Current Neurology and Neuroscience Reports, 4, 62-67.
73. Vitiello, B., Burnam, M. A., Bing, E. G., Beckman, R., & Shapiro, M. F. (2003). Use of psychotropic medications among HIV-infected patients in the United States. American Journal of Psychiatry, 160, 547-554.
74. von Giesen, H. J, Koller, H., de Nocker, D, Haslinger, B. A., & Arendt, G. (2003). Long-term safety and efficacy of NNRTI within the central nervous system. HIV Clinical Trials, 4, 382-390.
75. Wagner, G. J., Kanouse, D. E., Koegel, P., & Sullivan, G. (2003). Adherence to HIV antiretrovirals among persons with serious mental illness. AIDS Patient Care and STDs, 17, 179-186.
76. Williams, D., Geraci, A., & Simpson, D. M. (2002). AIDS and AIDS-treatment neuropathies. Current Pain and Headache Reports, 6, 125-130.
77. Wright, J. M., Sachdev, P. S., Perkins, R. J., & Rodriguez, P. (1989). Zidovudine-related mania. Medical Journal of Australia, 150, 339-341.
78. Wynn, H. E., Brundage, R. C., & Fletcher, C. V. (2002). Clinical implications of CNS penetration of antiretroviral drugs. CNS Drugs, 16, 595-609.
79. Yarchoan, R., Berg, G., Brouwers, P., Fischl, M. A., Spitzer, A. R., Wichman, A., et al. (1987). Response of human-immunodeficiency-virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet, 336, 132-135.